The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus

Pediatric Rheumatology

Volumn 12, Issue 1, 2014, Pages

  Bobek, Dubravka ^a   Grčević, Danka ^a   Kovačić, Nataša ^a   Lukić, Krešimir ^b   Jelušić, Marija ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF SPLIT   (Croatia)

Author keywords

High mobility group box 1; Juvenile idiopathic arthritis; Juvenile systemic lupus erythematosus; Solubile receptor for advanced glycation end products

Indexed keywords

ACUTE PHASE PROTEIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA GLOBULIN; C REACTIVE PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; HMGB1 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR;

ARTICLE; BLOOD LEVEL; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOSPLENOMEGALY; HUMAN; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SYNOVIAL FLUID; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; ARTHRITIS, JUVENILE; CASE CONTROL STUDY; ERYTHROCYTE SEDIMENTATION RATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; PRESCHOOL CHILD; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ALPHA-MACROGLOBULINS; ARTHRITIS, JUVENILE; BIOMARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; HMGB1 PROTEIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID;

EID: 84924165796     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-12-50     Document Type: Article

References (46)

1. Prakken B, Albani S, Martini A: Juvenile idiopathic arthritis. Lancet 2011, 377:2138-2149. 10.1016/S0140-6736(11)60244-4
2. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, Frühwald MC, Dassmann S, Pham TH, Roth J, Foell D: S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 2008,58(12):3924-3931. 10.1002/art.24137
3. Chirico V, Lacquaniti A, Salpietro V, Munafò C, Calabrò MP, Buemi M, Arrigo T, Salpietro C: High-mobility group box 1 (HMGB1) in childhood: from bench to bedside. Eur J Pediatr 2014,173(9):1123-1136. 10.1007/s00431-014-2327-1
4. Mellins ED, Macaubas C, Grom AA: Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011,7(7):416-426. 10.1038/nrrheum.2011.68
5. Sikora KA, Grom AA: Update on the pathogenesis and treatment of systemic idiopathic arthritis. Curr Opin Pediatr 2011,23(6):640-646. 10.1097/MOP.0b013e32834cba24
6. Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, Horwood N, Nanchahal J: Alarmins: awaiting a clinical response. J Clin Investig 2012, 122:8.
7. Oppenheim JJ, Yang D: Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005, 17:359-365. 10.1016/j.coi.2005.06.002
8. Yang D, de la Rosa G, Tewary P, Oppenheim JJ: Alarmins link neutrophils and dendritic cells. Trends Immunol 2009, 30:531-537. 10.1016/j.it.2009.07.004
9. Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
10. Lukić IK, Jelušić-Dražić M, Kovačić N, Grčević D: Damage-associated molecular patterns-emerging targets for biologic therapy of childhood arthritides. Inflamm Allergy Drug Targets 2009, 8:139-145. 10.2174/187152809788462617
11. Andersson U, Rauvala H: Introduction: HMGB1 in inflammation and innate immunity. J Internal Med 2011, 270:296-300. 10.1111/j.1365-2796.2011.02430.x
12. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A: HMGB: endogenous danger signaling. Mol Med 2008, 14:476-484.
13. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V: Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011,3(73):73ra20.
14. Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB: Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med 2007, 13:210-215.
15. Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M: HMGB1 in systemic lupus Erythematosus: its role in cutaneous lesions development. Autoimmun Rev 2010, 9:661-665. 10.1016/j.autrev.2010.05.015
16. Andersson U, Harris HE: The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 2010, 1799:141-148. 10.1016/j.bbagrm.2009.11.003
17. Magna M, Pisetsky DS: The Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases. Mol Med 2014,20(1):138-146.
18. Harris HE, Andersson U, Pisetsky DS: HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012,8(4):195-202. 10.1038/nrrheum.2011.222
19. Urbonaviciute V, Fürnrohr BG, Meister M, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE: Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008, 205:3007-3008. 10.1084/jem.20081165
20. Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR: Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus. Rheumatol Int 2012, 32:395-402. 10.1007/s00296-010-1636-6
21. Schiraldi M, Westra J, Bijl Marc: HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012, 209:551-563. 10.1084/jem.20111739
22. Van Zoelen MAD, Yang H, Florquin S, Meijers JC, Akira S, Arnold B, Nawroth PP, Bierhaus A, Tracey KJ, van der Poll T: Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock. 2009, 31:280-284. 10.1097/SHK.0b013e318186262d
23. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolitic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008, 22:3716-3727. 10.1096/fj.08-109033
24. Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M: Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheum 2009, 48:1190-1196. 10.1093/rheumatology/kep199
25. Moser B, Hudson BI, Schmidt AM: Solube RAGE: a hot new biomarker for the hot joint? Arthritis ResTher 2005, 7:142-144.
26. Rosenberg AM, Cordeiro DM: Relationship between seks and antibodies to high mobility group proteins 1 and 2 in juvenile idiopathic arthritis. J Rheumatol 2000, 27:2489-2493.
27. Wittemann B, Neuer G, Michels H, Truckenbrodt H, Bautz FA: Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum 1990, 33:1378-1383. 10.1002/art.1780330910
28. Schierbeck H, Pullerits R, Pruunsild C, Fischer M, Holzinger D, Laestadius Å, Sundberg E, Harris HE: HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J Rheumatol 2013,40(9):1604-1613. 10.3899/jrheum.120987
29. Kanakoudi-Tsakalidou F, Farmaki E, Tzimouli V, Taparkou A, Paterakis G, Trachana M, Pratsidou-Gertsi P, Nalbanti P, Papachristou F: Simultaneous changes in serum HMGB1 and IFN-α levels and in LAIR-1 expression on plasmatoid dendritic cells of patients with juvenile SLE. New therapeutic options? Lupus 2014, 23:305-312. 10.1177/0961203313519157
30. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM: Revision of the proposed classification criteria for juvenile idiopathis arthritis: Durban, 1997. J Rheumatol 1998, 25:1991-1994.
31. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
32. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing 2013 Edited by Vienna, Austria: URL http://www.R-project.org/
33. Siegel S, Castellan NJ: Non parametric statistics for the behavioural sciences. New York: MacGraw Hill Int; 1988:213-214.
34. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M: pROC: an open-source package for R and S + to analyze and compare ROC curves". BMC Bioinformatics 2011, 12:77. 10.1186/1471-2105-12-77
35. Cleveland WS: Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979,74(368):829-836. 10.1080/01621459.1979.10481038
36. Wang H, Yang H, Tracey KJ: Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004,255(3):320-331. 10.1111/j.1365-2796.2003.01302.x
37. Popović K, Ek M, Espinosa A, Podyukov L, Haris HE, Wahren-Herlenius M, Nyberg F: Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 2005, 52:3639-3645. 10.1002/art.21398
38. Barkauskaite V, Ek M, Popović K, Harris HE, Wahren-Herlenius M, Nyberg F: Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 2007, 16:794-802. 10.1177/0961203307081895
39. Qing X, Pitashny M, Thomas DB, Franck J, Barrat FJ, Hogarth MP, Putterman C: Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: Involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett 2008, 121:61-73. 10.1016/j.imlet.2008.08.007
40. Zickert A, Palmblad K, Sundelin B, Chavan S, Tracey KJ, Bruchfeld A, Gunnarsson I: Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 2012, 14:36.
41. Schaper F, Westra J, Bijl M: Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus. Mol Med 2014, 20:72-79.
42. Nienhuis HL, de Leeuw K, Bijzet J, Smit A, Schalkwijk CG, Graaff R, Kallenberg CG, Bijl M: Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatol (Oxford) 2008, 47:1554-1558. 10.1093/rheumatology/ken302
43. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, Andersson U, Harris HE: Successful therapy in collagen-induced arthritis in mice and rats targeting extracellular HMGB1 activity. Arthritis Rheum 2003,48(7):2052-2058. 10.1002/art.11161
44. Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T, Yamada S, Nagayama S, Hashiguchi K, Sunahara N, Fukuzaki K, Nagata R, Komiya S, Maruyama I, Fukuda T, Abeyama K: Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum 2008, 58:2675-2685. 10.1002/art.23729
45. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, Ulloa L, Yang H, Yan XJ, Furie R, Chiorazzi N, Tracey KJ, Andersson U, Harris HE: High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum 2002, 46:2598-2603. 10.1002/art.10540
46. Lukic A, Lukic IK, Malcic I, Batinic D, Milosevic D, Rozmanic V, Saraga M, Subat-Dezulovic M, Metlicic V, Malenica B, Jelusic M: Childhood-onset systemic lupus erythematosus in Croatia: demographic, clinical and laboratory features, and factors influencing time to diagnosis. Clin Exp Rheumatol 2013, 31:803-812.